I. Bodrogi

发表

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

David McDermott, R. Figlin, R. Motzer, 2007, The New England journal of medicine.

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

J. Machiels, K. Miller, P. Karakiewicz, 2012, European journal of cancer.

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

D. Campos, G. Romieu, P. Reichardt, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

R. Herbst, J. Heymach, J. Hou, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred.

D. Bishop, M. Stratton, K. Heimdal, 2010, Urologic oncology.

Somatic mutations of KIT in familial testicular germ cell tumours

Katherine M. Tucker, D. Easton, M. Stratton, 2004, British Journal of Cancer.

A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.

I. Bodrogi, A. Stenzl, J. Horti, 2009, Cancer biotherapy & radiopharmaceuticals.

Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

C. Sotiriou, C. Desmedt, D. Larsimont, 2004, Molecular cancer therapeutics.

A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary

P. Ágoston, I. Bodrogi, M. Dank, 2017, Pathology & Oncology Research.

Surmnary--The specific binding of luteinizing hormone-releasing hormone (LH-RH) agonist in estradiol-dependent MCF-7 and estradiol-independent MDA-MB-231 human breast cancer cells has been studied using [3H]Ovurelin [(1)-3H-Phe6),des-Glyt°-LH-RH-ethylamide]. The results of Scatchard analyses suggest

I. Bodrogi, I. Teplán, I. Pályi, 2002 .

Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenografts

I. Bodrogi, I. Teplán, S. Eckhardt, 1991, The Journal of Steroid Biochemistry and Molecular Biology.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

S. Fosså, S. Culine, A. Horwich, 2008, European urology.

Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment.

B. Szende, I. Bodrogi, L. Geczi, 2008, Anticancer research.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Bohuslav Melichar, A. Ravaud, B. Melichar, 2007, The Lancet.

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

P. Albers, M. Moore, I. Bodrogi, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC).

I. Tannock, N. James, S. Oudard, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.

R Sylvester, L Collette, L. Collette, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

L. Collette, S. Fosså, S. Kaye, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical relevance of HER-2/neu expression in germ-cell testicular tumors.

O. Csuka, I. Bodrogi, L. Geczi, 2004, Anticancer research.

Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy

I. Bodrogi, J. Horti, P. Tenke, 2007, International Urology and Nephrology.

A study of children, fathered by men treated for testicular cancer, conceived before, during, and after chemotherapy.

I. Bodrogi, M. Babosa, S. Gundy, 1994, Medical and pediatric oncology.

Expression of HER-2/neu in testicular tumors.

I. Bodrogi, L. Geczi, J. Tóth, 2003, Anticancer research.

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

C. Porta, A. Ravaud, R. Figlin, 2016, Clinical genitourinary cancer.

Increased predisposition to cancer in brothers and offspring of testicular tumor patients

I. Bodrogi, M. Babosa, S. Gundy, 2009, Pathology Oncology Research.

Expression of bcl‐2 in testicular carcinoma

I. Bodrogi, L. Geczi, M. Gulyás, 1998, Cancer.

Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer?

I. Bodrogi, E. Oláh, L. Geczi, 1997, Anticancer research.

The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary

I. Bodrogi, L. Geczi, F. Gomez, 2003, Journal of Cancer Research and Clinical Oncology.

Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors.

O. Csuka, I. Bodrogi, L. Geczi, 2005, Anticancer research.

Expression and prognostic value of the lung resistance-related protein (LRP) in germ cell testicular tumors.

O. Csuka, Z. Doleschall, I. Bodrogi, 2004, Anticancer research.

Multidrug resistance of testis cancers: the study of clinical relevance of P-glycoprotein expression.

I. Bodrogi, E. Oláh, B. Csókay, 1996, Anticancer research.

MRP expression of testicular cancers and its clinical relevance.

I. Bodrogi, M. Bak, L. Mingfang, 2000, Anticancer research.

Drug resistance and sensitivity of germ cell testicular tumors: evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins.

I. Bodrogi, L. Geczi, M. Bak, 1998, Anticancer research.

[Metallothionein expression as a marker of therapeutic sensitivity in the early stages of testicular cancer].

I. Bodrogi, M. Bak, E. Institóris, 1997, Orvosi hetilap.

Neutrophil-to-lymphocyte ratio in primary mediastinal germ cell tumors: A retrospective analysis of >20 years single institution experience.

I. Bodrogi, K. Biró, L. Geczi, 2020, Current problems in cancer.

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

W. Siegert, S. Fosså, S. Culine, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

The Effect of Intravesical Mitomycin C on the Recurrence of Superficial (Ta–T1) Bladder Cancer. A Hungarian Multicenter Study

I. Bodrogi, F. Törzsök, L. Kiss, 2004, International Urology and Nephrology.

Vinblastine, cisplatin and bleomycin (VPB) adjuvant therapy does not induce dose-dependent damage in human chromosomes.

I. Bodrogi, S. Gundy, M. Baki, 1989, Neoplasma.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

S. Fosså, S. Culine, A. Horwich, 2008, European urology.

The Y deletion gr/gr and susceptibility to testicular germ cell tumor.

M. Pike, M. Stratton, D. Forman, 2005, American journal of human genetics.

Genome-wide linkage screen for testicular germ cell tumour susceptibility loci.

M. Stratton, D. Forman, K. Heimdal, 2006, Human molecular genetics.

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

Stefania Tommasi, Laura Cortesi, Mads Thomassen, 2019, Cancer research.

Persistence of chromosomal aberrations in blood lymphocytes of testicular cancer patients. II. The effect of chemotherapy and/or radiotherapy.

A. Czeizel, I. Bodrogi, S. Gundy, 1990, Oncology.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

J. Machiels, S. Hansen, S. Oudard, 2010, The Lancet.

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

William Berry, Oliver Sartor, J Alfred Witjes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

K. Friedrichs, S. Chan, T. Pintér, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Cabazitaxel (CBZ) + Prednisone (P; CBZP) on Overall Survival (OS) At 2 Yrs and in Patients (PTS) with Aggressive Disease: Post-Hoc Analyses of Tropic Trial

J. Machiels, J. Bono, S. Oudard, 2012 .

HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel

D. Larsimont, M. Piccart, K. Friedrichs, 2004, Breast Cancer Research and Treatment.

Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors

D. Bishop, M. Stratton, K. Heimdal, 2008, Genes, chromosomes & cancer.

A PET study on the characterization of partially reversible radiogenic lower motor neurone disease

P. Ágoston, I. Bodrogi, Z. Lengyel, 2002, Spinal Cord.

Ifosfamide chemotherapy of metastatic renal cell cancer.

I. Bodrogi, S. Eckhardt, I. Sinkovics, 1988, Seminars in surgical oncology.

Do metallothioneins affect the response to treatment in testis cancers?

I. Bodrogi, L. Geczi, M. Bak, 1998, Journal of Cancer Research and Clinical Oncology.

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).

L. Collette, C. Théodore, I. Bodrogi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcome of Restarted Sunitinib Treatment in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Trial and Combined Case Reports from Literature

I. Bodrogi, Z. Küronya, K. Biró, 2017, Pathology & Oncology Research.

mdm-2 expression in human testicular germ-cell tumors and its clinical value.

I. Bodrogi, L. Geczi, M. Bak, 1999, Anticancer research.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Three-Year Results of the First Educational and Early Detection Program for Testicular Cancer in Hungary

I. Bodrogi, Z. Horváth, L. Geczi, 2001, Oncology.

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

E. Juhász, I. Bodrogi, J. Horti, 2008, Cancer Chemotherapy and Pharmacology.

Significance of examination of prostate-specific antigen and prostate-specific antigen density in patients with prostatic hyperplasia and prostate cancer

I. Bodrogi, I. Romics, D. Frang, 2006, International Urology and Nephrology.

Younger age-at-diagnosis for familial malignant testicular germ cell tumor

Bingshu E. Chen, M. Stratton, K. Heimdal, 2009, Familial Cancer.

Characteristics and Risk Factors of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients Detected by Distorsion Product Otoacoustic Emission

I. Bodrogi, K. Biró, L. Geczi, 2006, Oncology.

Thoracic surgery of testicular cancer patients.

I. Bodrogi, I. Besznyák, M. Bak, 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Glutathione related enzymes in human testicular germ cell tumors and normal testes.

I. Bodrogi, M. Bak, E. Institóris, 1995, Anticancer research.

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

I. Bodrogi, P. Conte, L. Dogliotti, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Forms and results of mitolactol therapy.

I. Bodrogi, J. Szántó, I. Hindy, 1980, Oncology.

[Metachronous metastasis from rectal adenocarcinoma to the penis--case report].

I. Bodrogi, Z. Pápai, Z. Küronya, 2009, Magyar Onkológia.

Persistence of chromosomal aberrations in blood lymphocytes of testicular cancer patients. I. The effect of vinblastine, cisplatin and bleomycin adjuvant therapy.

A. Czeizel, I. Bodrogi, S. Gundy, 1990, Oncology.

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

I. Bodrogi, P. Conte, H. von der Maase, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Multidrug resistance of testicular cancers. (Detection of P-glycoprotein and MDR1 gene expression and their clinical connection)].

I. Bodrogi, E. Oláh, B. Csókay, 1995, Orvosi hetilap.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

J. Machiels, S. Hansen, S. Oudard, 2010, The Lancet.

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

S. Chan, T. Pintér, I. Bodrogi, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for survival in the phase III TROPIC trial.

S. Oudard, I. Bodrogi, G. Gravis, 2012, Journal of Clinical Oncology.

PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.

J. Carles, J. Bono, V. Matveev, 2013 .

A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), “Mayo regimen”, in first line palliative chemotherapy patients (pts) with metastatic colorectal cancer (MCRC)

N. Noël, I. Bodrogi, S. Pyrhönen, 1999 .

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).

L. Collette, C. Théodore, I. Bodrogi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.